A Systems Biology Approach towards Predictive Cancer Therapy

Transcription

1 FORSYS-Partner Stuttgart A Systems Biology Approach towards Predictive Cancer Therapy Holistic Multi Scale Modelling of Targeted Protein Therapeutics Action Kick-Off Meeting September 2008

2 Project Partners Universität Stuttgart Universität Tübingen Robert Bosch Hospital Stuttgart FORSYS Magdeburg Industrial Partners P1 Prof. Klaus Pfizenmaier, Prof. Roland Kontermann, Institute of Cell Biology and Immunology, University Stuttgart P2 Prof. Peter Scheurich, Institute of Cell Biology and Immunology, University Stuttgart P3 Bernd J Pichler, PD, Laboratory for Preclinical Imaging and Imaging Technology, University of Tübingen P4 Prof. Dr. med. Matthias Schwab 1,2, PD Dr. med. Godehard Friedel 3, PD Dr. German Ott 3, Dr. rer. nat. Thomas Mürdter 1,2, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) 1, Department of Clinical Pharmacology, University Hospital, Tuebingen 2 and Robert-Bosch-Hospital, Stuttgart 3. P5 Prof. Dr.- Ing. Dr.- h.c. Matthias Reuss, Institute of Biochemical Engineering and Centre Systems Biology, University Stuttgart. P6 FORSYS Magdeburg, Prof. Dr. Wolfgang Marwan 1,2, Prof. Dr Robert Weismantel 3, Dr.-Ing. Rolf Findeisen 4, 1 Max Planck Institute Dynamik komplexer technischer Systeme, Magdeburg; 2 Institute for Biology, 3 Institute of Mathematical Optimization and 4Institute of Automatic Control and Systems Theory, University of Magdeburg. P7 Prof. Frank Allgöwer, Institute for Systems Theory and Automatic Control, University Stuttgart P8 Prof. Rainer Helmig, Institute for Hydraulic Engineering, Dept. of Hydromechanics and Modelling of Hydrosystems, University of Stuttgart P9 Celonic GmbH, Jülich, Dr. Andreas Herrmann P10 Bayer Technology Services, Competence Center Systems Biology, Dr. Jörg Lippert

3 Our goals in the project Predictive Cancer Therapy Establishment of a holistic mathematical model supporting clinical evaluation and reducing time to approval of new therapeutics Investigating the therapeutic potential of targeted death ligands

4 Targeting as therapeutic concept Schrama, Reisfeld, Becker, Nature Rev Drug Discov 5, (2006)

5

6 Tasks of P1 in Predictive Cancer Therapy Genetic engineering and functional analyses (in vitro/in vivo) of targeted therapeutics triggering death receptors 1. scfv-ligand fusion proteins 2. Multifunctional nanoparticulate carriers

7 The therapeutic concept: Optimum death ligand activation by membrane targeting Tumor antigen Tumor or stroma cell, target positive juxtatropic signal Tumor or stroma cell, target negative autotropic signal FORSYS Partner Predictive Cancer Therapy Example: Kick-Off targeting Meeting FasL Antigen negative tumor Antigen positive tumor Untreated control Tumor targeted death ligand Untreated control Tumor targeted death ligand

8 Schrama, Reisfeld, Becker, Nature Rev Drug Discov 5, (2006)

9 Prototype scfv-trail Fusion Proteins Molecular Characteristics α-erbb2 sctrail α-erbb2 TRAIL scfv: α-erbb2 scfv F: Flag tag

10 Targeting improves bioactivity

11 Targeting improves bioactivity Events HT1080 α-c-erbb FL1 LOG 10µg/ml Interference with erbb2 binding of the fusion protein reduces TRAIL induced cell death

12 In vivo tumor regression in a Xenotransplantation model Treatment: 4 daily p.t. injections (10µmol/day). strongest anti-tumor activity of α-erbb2-sctrail

13 Superior anti tumoral action upon targeting of sctrail

14 Biofunctionalized nanoparticles: Composite multifunctional particles for targeted activity scfv-vermittelte Bindung an Zielzellen Zielzell- Antigen lokale Destabilisierung derhülle durch proteolytische Abspaltung der PEG-Ketten lokale Freisetzung der TNF-Nanocytes TNF-Nanocytevermittelter Zelltod (Apoptose ) durch Bindung an TNF-Rezeptoren TNF- Rezeptoren sezernierte tumorassoziierte Proteinasen Funktionsbaustein 1: TNF-Nanocyte Funktionsbaustein 2: Lipid-Hülle Funktionsbaustein 3: PEG-scFv = Ligand Funktionsbaustein 4: spaltbares Peptid-PEG-Lipid Messerschmidt, submitted

15 Present activities of P1 New molecules under construction Second generation sctrail w/ modified linkers Humanization of erbb1/2 spec. scfv Cys-linker humanized scfv and sctrail for conjugation to nanoparticulate carriers erbb1-sctrail fusion proteins based on hu-scfv erbb2-sctrail fusion proteins based on hu-scfv state done done, analyses done, Trail vector delivered carrier conjugation establ. construct finished under construction Xenotransplant.mouse tumor models (Colo205, A431) established Production of stroma targeted sctnf and FAP specific minibodies for labeling and imaging (by P3) ongoing

16 Facs analyses of specific binding of the newly generated, humanized scfv erbb1 specific scfv on A431 erbb2 specific scfv on SKBR3 Zellen (SKBR3) Detektionssystem hu scfv4d5 (10 µg/ml) hu scfv4d5 (10 µg/ml) hu scfvc225 (10 µg/ml) scfv 33 (1 µg/ml; Kontrolle auf unspezifische Bindung) Events FL1 Log

17 Immunoliposome binding to target cells Events FL2 Log 5 nmol IL scfv C225 (0.1 mol% mal Peg) Zellen (A431) mpeg, neg Kontrolle + 1 µg/ml scfv + 10 µg/ml scfv µg/ml scfv Pos. Kontrolle (ohne Blockierung)

18 Next steps Finish new constructs, submit to Celonics for production Establishment of erbb specific ELISA (w/ RBK) for PK studies First PK studies in mice with clinical erbb specific mabs (together with P3/P4) Analyse functional activity of rec. proteins in vitro upon delivery by Celonics Generation of sctrail- and targeted sctrail-nanoparticles